Shevrin D H, Gorny K I, Rosol T J, Kukreja S C
Department of Medicine, University of Illinois.
Prostate. 1991;19(2):149-54. doi: 10.1002/pros.2990190208.
We have established an animal model of bone metastasis using the PC-3 human prostate tumor cell line. In order to assess whether inhibition of bone resorption would prevent the development of bone metastasis, the diphosphonate etidronate (EHDP) was administered to 20 mice at a dose of 30 mg/kg subcutaneously daily starting 2 days prior to injection of tumor cells. Control mice received daily injections of the saline vehicle. In the EHDP-treated mice, there was no significant reduction in the incidence of bone metastasis, the size of the lesions, or the number of bone lesions per mouse. Approximately 50% of the mice developed bone metastasis, which was similar to the control group and similar to what was observed in earlier studies with this animal model. Histomorphometric analysis of bones showed marked inhibition of mineralization in EHDP-treated mice, thus indicating biological effect on the bone. Therefore, the use of EHDP in biologically effective doses failed to reduce the incidence, size, or number of bone metastases in this animal model.
我们使用PC-3人前列腺肿瘤细胞系建立了骨转移动物模型。为了评估抑制骨吸收是否会阻止骨转移的发展，从注射肿瘤细胞前两天开始，每天以30 mg/kg的剂量皮下注射双膦酸盐依替膦酸（EHDP）给20只小鼠。对照小鼠每天注射生理盐水。在接受EHDP治疗的小鼠中，骨转移的发生率、病变大小或每只小鼠的骨病变数量均未显著降低。约50%的小鼠发生了骨转移，这与对照组相似，也与该动物模型早期研究中观察到的情况相似。对骨骼的组织形态计量学分析显示，接受EHDP治疗的小鼠矿化受到明显抑制，从而表明对骨骼有生物学效应。因此，在该动物模型中，使用生物有效剂量的EHDP未能降低骨转移的发生率、大小或数量。
